With Kenai Therapeutics making a splash by emerging from stealth with an $82 million Series A funding round, 2024 is shaping up to be a pivotal year for iPSC drug developers eager to highlight the potential of their pipelines in anticipation of the next investment wave.

The 4th iPSC Drug Development & Manufacturing Summit brings together two leading iPSC conferences—iPSC-Derived Cell Therapies and iPSC Manufacturing—into a single, flagship event. This summit will feature groundbreaking advancements across research, development, manufacturing, and analytical techniques, ensuring participants remain at the cutting edge of the iPSC cell therapy revolution.

The event is divided into two key tracks: Research & Development and Manufacturing & Analytical Development, making it the go-to gathering for drug developers and academic leaders aiming to streamline their path to clinical trials and optimize their manufacturing processes.